GSK Cancer R&D Chief Sees Three Key Approvals In Q2

Says “Will Help Anchor” Oncology Pipeline.

 
• By Sten Stovall

GlaxoSmithKline expects regulatory approval for three key cancer products by the middle of this year, anchoring it as a leading oncology company, Axel Hoos tells Scrip.

Cancer_Research
Axel Hoos says GSK is successfully re-entering oncology’s commercial space • Source: Shutterstock

More from New Products

More from Scrip